Literature DB >> 11823128

PET studies of 18F-memantine in healthy volunteers.

S M Ametamey1, M Bruehlmeier, S Kneifel, M Kokic, M Honer, M Arigoni, A Buck, C Burger, S Samnick, G Quack, P A Schubiger.   

Abstract

Previous studies in mice and PET investigations in a Rhesus monkey showed that the regional uptake of 18F-memantine could be blocked by pharmacological doses of memantine and (+)-MK-801. In the present study, the binding characteristics of 18F-memantine was examined in five healthy volunteers. In humans, 18F-memantine was homogeneously distributed in gray matter i.e. cortex and basal ganglia regions, as well as the cerebellum. No radioactive metabolites were detected in plasma during the time-frame of the PET studies. The uptake of 18F-memantine in receptor-rich regions such as striatum and frontal cortex could be well described by a 1-tissue compartment model. The DV" values of all gray matter regions were similar and ranged from 15 to 20 ml/ml. The white matter showed lower DV" values of 15 +/- 1.4 ml/ml. These results suggest that 18F-memantine distribution in human brain does not reflect the regional NMDA receptor concentration, and therefore, this radioligand is not suitable for the PET imaging of the NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823128     DOI: 10.1016/s0969-8051(01)00293-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

Review 1.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

2.  The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models.

Authors:  Fangcheng Luo; Liangmiao Wu; Zhixiang Zhang; Zeyu Zhu; Zheng Liu; Baojian Guo; Ning Li; Jun Ju; Qiang Zhou; Shupeng Li; Xifei Yang; Shinghung Mak; Yifan Han; Yewei Sun; Yuqiang Wang; Gaoxiao Zhang; Zaijun Zhang
Journal:  Br J Pharmacol       Date:  2019-07-31       Impact factor: 8.739

Review 3.  Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Shinji Matsunaga; Taro Kishi; Nakao Iwata
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-28       Impact factor: 5.176

4.  First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors.

Authors:  Jasper van der Aart; Sandeep S V Golla; Marieke van der Pluijm; Lothar A Schwarte; Robert C Schuit; Pieter J Klein; Athanasios Metaxas; Albert D Windhorst; Ronald Boellaard; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  EJNMMI Res       Date:  2018-07-27       Impact factor: 3.138

5.  The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs.

Authors:  Jan Bures; Jaroslav Kvetina; Vera Radochova; Ilja Tacheci; Eva Peterova; David Herman; Rafael Dolezal; Marcela Kopacova; Stanislav Rejchrt; Tomas Douda; Vit Sestak; Ladislav Douda; Jana Zdarova Karasova
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

Review 6.  A Review of Molecular Imaging of Glutamate Receptors.

Authors:  Jong-Hoon Kim; János Marton; Simon Mensah Ametamey; Paul Cumming
Journal:  Molecules       Date:  2020-10-16       Impact factor: 4.411

7.  Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease.

Authors:  Simon Couly; Morgane Denus; Mélanie Bouchet; Gilles Rubinstenn; Tangui Maurice
Journal:  Int J Neuropsychopharmacol       Date:  2021-02-15       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.